The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development ...

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd ...

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...

Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B.

The second half of Alan Jackson’s farewell tour resumes next week. The country music legend will perform on Saturday, Jan. 18 ...

A woman in Georgia has filed a police report after an online scammer claiming to be Alan Jackson swindled her out of nearly ...

(Alliance News) - RTW Biotech Opportunities Ltd said on Friday said it is participating in a EUR65 million Series A financing round for Alesta Therapeutics BV, a Leiden, Netherlands-based ...

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop ...

Results from the ESTABLISH1 observational study confirms that neuromuscular junction (NMJ) dysfunction is an underappreciated disease characteristic in patients with Charcot-Marie-Tooth disease ...

Stem cells offer new treatments for Parkinsons, diabetes, and epilepsy by 2025 Stem cells revolutionize possibilities for ...